| Objective(s): Hypercholesterolemia is a common metabolic disorder in developing and developed
countries and is associated with the increased rates of chronic kidney disease (CKD). Statin therapy
could reduce cholesterol synthesis as well as progression of CKD. Diversity between statins causes
variety in pharmacokinetics and pharmacodynamics and also their pleiotropic effects. In the present
investigation we aimed to evaluate the protective potentials of both atorvastatin (Ator) (as lipidsoluble
statin) and rosuvastatin (Ros) (as water-soluble statin) against renal histopathological
damages in the high cholesterol diet induced hypercholesterolemic rats (HCDIHR).
Materials and Methods: Serum lipid profile, oxidized low density lipoprotein (OX-LDL), malondialdehyde
(MDA), urea and creatinine levels, as well as renal histopathology were evaluated.
Results: While Ros acted better than Ator to reduce serum low density lipoprotein cholesterol (LDL-C)
(P<0.01), atherogenic index (AI) (P<0.01), MDA (P<0.01), and OX-LDL (P<0.01); no significant
differences were noted in their cholesterol (P=0.72), triglyceride (TG) (P=0.79), and very low density
lipoprotein cholesterol lowering (VLDL-C) (P=0.79) and high density lipoprotein cholesterol elevating
effects (HDL-C) (P=0.72). Ator was more effective to reduce renal histopathologic indices compared to
Ros, including accumulation of lipid droplet, glomerular foam cells, mesangial cell proliferation, renal
hemorrhage, and tubulointerstitial damages in the kidneys of diet induced hypercholesterolemic rats.
Conclusion: The findings underline that the lipophilic Ator may performs better than Ros in attenuating
renal damages in HCDIHR. |